Back to results
US 8,288,352 B2Granted
Auristatins having an aminobenzoic acid unit at the N terminus
AssigneeSeattle Genetics, Inc.
InventorsSvetlana O. Doronina, Brian A. Mendelsohn
Life of this patent
Estimating the term…
Abstract
Auristatin-type peptides are disclosed which are highly cytotoxic, synthetically accessible, and can be conjugated to antibodies and other ligands.
Claims28
A Conjugate Compound having the Formula Ia:
- or a pharmaceutically acceptable salt thereof;
- wherein:
- L- is a Ligand Unit;
- -Aa-Ww— is a Linker Unit (LU), wherein:
- -A- is a Stretcher Unit,
- a is 0 or 1,
- each —W— is independently an Amino Acid Unit,
- w is an integer ranging from 0 to 12,
- p is an integer ranging from 1 to about 20;
- and
- -D is a Drug Unit of the formula
- wherein independently at each location:
- R2 is selected from the group consisting of -hydrogen, —C1-C8 alkyl, —O—(C1-C8 alkyl), -halogen, —NO2, —COOH, and —C(O)OR11;
- each R3 is selected independently from the group consisting of -hydrogen and —C1-C8alkyl;
- I is an integer ranging from 0-10;
- R4 is selected from the group consisting of -hydrogen, —C1-C8 alkyl, —C3-C8 carbocycle, -aryl, —C1-C8 alkyl-aryl, —C1-C8 alkyl-(C3-C8 carbocycle), —C3-C8 heterocycle and —C1-C8 alkyl-(C3-C8 heterocycle);
- and R5 is selected from the group consisting of —H and -methyl;
- or R4 and R5 jointly have the formula —(CRaRb)n—, wherein Ra and Rb are independently selected from the group consisting of —H, —C1-C8 alkyl and —C3-C8 carbocycle, n is selected from the group consisting of 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;
- R6 is selected from the group consisting of —H and —C1-C8 alkyl;
- R7 is selected from the group consisting of —H, —C1—C8 alkyl, —C3-C8 carbocycle, aryl, —C1-C8 alkyl-aryl, —C1-C8 alkyl-(C3-C8carbocycle), —C3-C8 heterocycle and —C1-C8 alkyl-(C3-C8 heterocycle);
- each R8 is independently selected from the group consisting of —H, —OH, —C1-C8 alkyl, —C3-C8 carbocycle, —O-alkyl-(C1-C8 carbocycle) and —O—(C1-C8 alkyl);
- R9 is selected from the group consisting of —H and —C1-C8 alkyl;
- R10 is selected from the group consisting of aryl group and —C3-C8 heterocycle;
- Z is selected from the group consisting of —O—, —S—, —NH—, and —NR12— where R12 is C1-C8 alkyl or aryl;
- and
- R11 is selected from the group consisting of —H, C1-C8 alkyl, aryl, —C3-C8 heterocycle, —(CH2CH2O)r—H, —(CH2CH2O)r—CH3, and —(CH2CH2O)r—CH2CH2C(O)OH;
- wherein r is an integer ranging from 1-10.
24 more elements
A Drug Compound having the Formula I:
- or a pharmaceutically acceptable salt or solvate thereof;
- wherein, independently at each location:
- R2 is selected from the group consisting of -hydrogen —C1-C8 alkyl, —O—(C1-C8 alkyl), -halogen, —NO2, —COOH, and —C(O)OR″;
- each R3 is selected independently from the group consisting of -hydrogen and —C1-C8 alkyl;
- I is an integer ranging from 0-10;
- R4 is selected from the group consisting of -hydrogen, —C1-C8 alkyl, —C3-C8 carbocycle, -aryl, —C1-C8 alkyl-aryl, —C1-C8 alkyl-(C3-C8 carbocycle), —C3-C8 heterocycle and —C1-C8 alkyl-(C1-C8 heterocycle);
- R5 is selected from the group consisting of —H and -methyl;
- or R4 and R5 jointly have the formula —(CRaRb)n—, wherein Ra and Rb are independently selected from the group consisting of —H, —C1-C8 alkyl and —C3-C8 carbocycle and n is selected from the group consisting of 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;
- R6 is selected from the group consisting of —H and —C1-C8 alkyl;
- R7 is selected from the group consisting of —H, —C1-C8 alkyl, —C3-C8 carbocycle, aryl, —C1-C8 alkyl-aryl, —C1-C8 alkyl-(C3-C8 carbocycle), —C3-C8 heterocycle and —C1-C8 alkyl-(C3-C8 heterocycle);
- each R8 is independently selected from the group consisting of —H, —OH, —C1-C8 alkyl, —C3-C8 carbocycle, —O-alkyl-(C1-C8 carbocycle) and —O—(C1-C8 alkyl);
- R9 is selected from the group consisting of —H and —C1-C8 alkyl;
- R10 is selected from the group consisting of aryl group and —C3-C8 heterocycle;
- Z is selected from the group consisting of —O—, —S—, —NH—, and —NR12—where R12 is C1-C8 alkyl;
- or aryl;
- and
- R11 is selected from the group consisting of —H, C1-C8 alkyl, aryl, —C3-C8 heterocycle, —(CH2CH2O)r—H, —(CH2CH2O)r—CH3, and —(CH2CH2O)r—CH2CH2C(O)OH;
- wherein r is an integer ranging from 1-10.
15 more elements
A Linker Drug Conjugate having the following formula:
- or a pharmaceutically acceptable salt thereof.
A Linker Drug Conjugate having the following formula:
- or a pharmaceutically acceptable salt thereof.
A Linker Drug Conjugate having the following formula:
- or a pharmaceutically acceptable salt thereof.
A Linker Drug Conjugate having the following formula:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.